<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649426</url>
  </required_header>
  <id_info>
    <org_study_id>CLN 0777</org_study_id>
    <nct_id>NCT02649426</nct_id>
  </id_info>
  <brief_title>A Study of the ReCor Medical Paradise System in Clinical Hypertension</brief_title>
  <acronym>RADIANCE-HTN</acronym>
  <official_title>The &quot;RADIANCE-HTN&quot; Study. A Study of the ReCor Medical Paradise System in Clinical Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReCor Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReCor Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO)
      designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation
      System in two distinct populations of hypertensive subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with essential hypertension controlled on 1 or 2 antihypertensive medications or
      uncontrolled on 0-2 antihypertensive medications will be included in the RADIANCE Solo cohort
      while subjects with treatment resistant hypertension on a minimum of 3 antihypertensive
      medications will be included in the RADIANCE Trio cohort. Prior to randomization, subjects
      will be hypertensive in the absence of hypertension medication (SOLO) or despite the presence
      of a stabilized, single pill, triple, fixed dose antihypertensive medication regimen (TRIO).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean reduction in average daytime ambulatory systolic BP</measure>
    <time_frame>from baseline to 2 months post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in average 24-hr/night-time ambulatory systolic BP</measure>
    <time_frame>from baseline to 2 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in average daytime/24-hr/night-time diastolic BP</measure>
    <time_frame>from baseline to 2 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertensive or hypotensive emergency resulting in hospitalization</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke, transient ischemic attack, cerebrovascular accident</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End stage renal disease</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal artery or vascular complications requiring intervention</measure>
    <time_frame>from baseline to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant embolic events resulting in end organ damage</measure>
    <time_frame>from baseline to 1 month and 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related pain lasting &gt; 2 days</measure>
    <time_frame>from baseline to 1 month and 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal injury</measure>
    <time_frame>from baseline to 1 month and 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant (&gt;50%) and severe (&gt;75%) new onset renal stenosis</measure>
    <time_frame>from baseline to 6, 12, 24 and 36 months post-procedure</time_frame>
    <description>as diagnosed by duplex ultrasound and confirmed by renal CTA/MRA or as diagnosed/confirmed by study defined renal CTA/MRA at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major access site complications</measure>
    <time_frame>from baseline to 1 month and 36 months post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Hypertension</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Ultrasound Renal Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the TRIO or SOLO cohorts that are randomized to treatment, will receive renal denervation following a renal angiogram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>For subjects in TRIO or SOLO cohorts that randomize to the sham procedure, the diagnostic renal angiogram intervention will be considered the sham procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Paradise® Renal Denervation Ultrasound System</intervention_name>
    <description>Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.</description>
    <arm_group_label>Ultrasound Renal Denervation</arm_group_label>
    <other_name>renal denervation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.</description>
    <arm_group_label>Sham Procedure</arm_group_label>
    <other_name>renal angiogram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        TRIO and SOLO Inclusion Criteria:

          -  Appropriately signed and dated informed consent

          -  Age ≥18 and ≤75 years at time of consent

          -  Documented history of essential hypertension

          -  SOLO Cohort only: Either an average seated office BP &lt; 180/110 mmHg at screening visit
             while on a stable regimen of 1 or 2 antihypertensive medications for at least 4 weeks
             prior to consent or an average seated office BP ≥ 140/90 mmHg &lt;180/110 mmHg despite
             lifestyle measures on no antihypertensive medications

          -  TRIO Cohort only: Average seated office BP ≥ 140/90 mmHg at screening visit while on a
             stable regimen of at least 3 antihypertensive medications of different classes
             including a diuretic for at least 4 weeks prior to consent

          -  Documented daytime ABP ≥ 135/85 mmHg and &lt; 170/105 mmHg after 4-week washout/run-in
             period (SOLO cohort) or after 4-week stabilization period (TRIO cohort)

          -  Suitable renal anatomy compatible with the renal denervation procedure and documented
             by renal CTA or MRA of good quality performed within one year prior to consent (a CTA
             or MRA will be obtained in patients without a recent (≤1 year) renal imaging)

          -  Able and willing to comply with all study procedures

        Solo Exclusion Criteria:

          -  Renal artery anatomy on either side, ineligible for treatment including:

               -  Main renal artery diameter &lt; 4 mm and &gt; 8 mm

               -  Main renal artery length &lt; 25 mm

               -  A single functioning kidney

               -  Presence of abnormal kidney (or secreting adrenal) tumors

               -  Renal artery with aneurysm

               -  Pre-existing renal stent or history of renal artery angioplasty

               -  Prior renal denervation procedure

               -  Fibromuscular disease of the renal arteries

               -  Presence of renal artery stenosis of any origin ≥ 30%

               -  Accessory arteries with diameter ≥ 2mm &lt;4 mm and &gt; 8 mm*

          -  Evidence of active infection within 7 days of procedure

          -  Iliac/femoral artery stenosis precluding insertion of the Paradise Catheter

          -  Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma Hb1Ac ≥
             9.0%)

          -  Documented history of chronic active inflammatory bowel disorders such as Chrohn's
             disease or ulcerative colitis

          -  eGFR of &lt;40 mL/min/1.73 m2 (by Modification of Diet in Renal Disease formula)

          -  Brachial circumference ≥ 42 cm

          -  Any history of cerebrovascular event (e.g. stroke, transient ischemic event,
             cerebrovascular accident)

          -  Any history of severe cardiovascular event (myocardial infarction, CABG, acute heart
             failure requiring hospitalization (NYHA III-IV)

          -  Documented confirmed episode(s) of stable or unstable angina

          -  Documented repeat (&gt;1) hospitalization for hypertensive crisis within the prior 12
             months

          -  Prescribed to any standard antihypertensive of cardiovascular medication (e.g. beta
             blockers) for other chronic conditions (e.g. ischemic heart disease) such that
             discontinuation might pose serious risk to health

          -  Documented history of persistent or permanent atrial tachyarrhythmia

          -  Active implantable medical device (e.g. ICD or CRT-D; neuromodulator/spinal
             stimulator; baroreflex stimulator)

          -  Chronic oxygen support or mechanical ventilation other than nocturnal respiratory
             support for sleep apnea.

          -  Primary pulmonary hypertension

          -  Documented contraindication or allergy to contrast medium not amenable to treatment

          -  Limited life expectancy of &lt; 1 year at the discretion of the Investigator

          -  Any known, unresolved history of drug use or alcohol dependency, lacks the ability to
             comprehend or follow instructions, or for any reason in the opinion of the
             investigator, would be unlikely or unable to comply with study protocol requirements
             or whose participation may result in data analysis confounders (e.g. night shift
             workers)

          -  Pregnant, nursing or planning to become pregnant (negative pregnancy test required,
             documented within a maximum of 7 days prior to procedure for all women of child
             bearing potential. Documentation of effective contraception is also required for women
             of child bearing potential) Concurrent enrollment in any other investigational drug or
             device trial (participation in non-interventional Registries is acceptable)

        TRIO Exclusion Criteria

          -  Renal artery anatomy on either side, ineligible for treatment including:

               -  Main renal artery diameter &lt; 3.5 mm and &gt; 8 mm

               -  Main renal artery length &lt; 20 mm

               -  A single functioning kidney

               -  Presence of abnormal kidney tumors

               -  Renal artery with aneurysm

               -  Pre-existing renal stent or history of renal artery angioplasty

               -  Pre-existing aortic stent or history of aortic aneurysm

               -  Prior renal denervation procedure

               -  Fibromuscular disease of the renal arteries

               -  Presence of renal artery stenosis of any origin ≥ 30%

               -  Accessory arteries with diameter ≥2 mm &lt;3.5 mm and &gt; 8 mm*

          -  Iliac/femoral artery stenosis precluding insertion of the Paradise Catheter

          -  Evidence of active infection within 7 days of procedure

          -  Secondary hypertension not including sleep apnea (documented through clinical work up
             within the 12 months prior to consent- see protocol body for details)

          -  Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma Hb1Ac ≥
             9.0%)

          -  Documented history of chronic active inflammatory bowel disorders such as Crohn's
             disease or ulcerative colitis

          -  eGFR of &lt;40 mL/min/1.73 m2 (by Modification of Diet in Renal Disease formula)

          -  Brachial circumference ≥ 42 cm

          -  Any history of cerebrovascular event (e.g. stroke, transient ischemic event,
             cerebrovascular accident) within 3 months prior to consent

          -  Any history of severe cardiovascular event (e.g. myocardial infarction, CABG, acute
             heart failure requiring hospitalization (NYHA III-IV) within 3 months prior to consent

          -  Documented repeat (&gt;1) hospitalization for hypertensive crisis within the prior 3
             months

          -  Documented confirmed episode(s) of unstable angina within 3 months prior to consent

          -  Documented intolerance or contraindication for any of the antihypertensive drugs
             prescribed as a requirement of the study protocol

          -  Prescribed to any standard anti-hypertensive CV medication (other than beta blockers)
             for other chronic conditions (e.g. ischemic heart disease) such that discontinuation
             might pose serious risk to health

          -  Documented history of persistent or permanent atrial tachyarrhythmia

          -  Active implantable medical device (e.g. ICD or CRT-D; neuromodulator/spinal
             stimulator; baroreflex stimulator)

          -  Chronic oxygen support or mechanical ventilation other than nocturnal respiratory
             support for sleep apnea.

          -  Primary pulmonary hypertension

          -  Documented contraindication or allergy to contrast medium not amenable to treatment

          -  Limited life expectancy of &lt; 1 year at the discretion of the Investigator

          -  Night shift workers

          -  Any known, unresolved history of drug use or alcohol dependency, lacks the ability to
             comprehend or follow instructions, or for any reason in the opinion of the
             investigator, would be unlikely or unable to comply with study protocol requirements
             or whose participation may result in data analysis confounders

          -  Pregnant, nursing or planning to become pregnant (documented negative pregnancy test
             required documented within a maximum of 7 days prior to procedure for all women of
             child bearing potential. Documentation of effective contraception is also required for
             women of child bearing potential)

          -  Concurrent enrollment in any other investigational drug or device trial (participation
             in non-interventional Registries is acceptable)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Azizi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges-Pompidou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ajay J Kirtane, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Health Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridgeport Hospital</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stamford Hospital</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cardiac and Vascular Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Health Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Heart and Vascular Insitute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munson Medical Center</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renown Institute for Heart&amp; Vascular Health</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University / NewYork Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-André - CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Institut Coeur Poumon</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Dusseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg-Bad Krozingen GmbH</name>
      <address>
        <city>Freiburg</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic of Saarland</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Kliniken Lübeck GmbH</name>
      <address>
        <city>Lübeck</city>
        <zip>23560</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Hospital</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>England</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW7 2AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Essex Cardiothoracic Centre - Basildon &amp; Thurrock University Hospitals</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital (Wonford)</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conquest Hospital - Hastings</name>
      <address>
        <city>Hastings</city>
        <zip>TN37 7RD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>denervation</keyword>
  <keyword>resistant hypertension</keyword>
  <keyword>essential hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>to be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

